Ranbaxy Daiichi Deal

The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.

Malvinder Singh and his brother Shivinder Singh, ex-promoters of pharmaceutical giant Ranbaxy, were raided today by the Enforcement Directorate in a Rs 740-crore fraud case. against the former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh.

Billionaire Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been asked to pay nearly Rs 2,600 crore in fine to Daiichi Sankyo, for "suppressing and misrepresenting" facts about the 2008 deal involving the sale of controlling stake in Ranbaxy to the Japanese drugmaker.

The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.

It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.

The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo, which holds majority stake in the former, said today.

Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.

Ramesh Adige, former executive director of Ranbaxy told NDTV's Prashant Nair that Sun Pharma's acquisition of Ranbaxy for $3.2 billion is a win-win situation for all stakeholders, except Daiichi, which is the controlling shareholder in Ranbaxy.

Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...

Ranbaxy, India's biggest company by sales, is controlled by Japan's Daiichi Sankyo. All of its local units have been under the scanner of the US Food and Drug Administration for manufacturing violations. Currently, Ranbaxy cannot export generic drugs to the US, which is its most important market.

Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.

The apex court on November 15, 2019 had held former Ranbaxy promoters guilty of contempt of court for violating its order asking them not to divest their shares in FHL.

Malvinder Singh and his brother Shivinder Singh, ex-promoters of pharmaceutical giant Ranbaxy, were raided today by the Enforcement Directorate in a Rs 740-crore fraud case. against the former promoters of pharmaceutical company Ranbaxy, Malvinder Mohan Singh and his brother Shivinder Mohan Singh.

Billionaire Malvinder Mohan Singh and his younger brother Shivinder Mohan Singh have been asked to pay nearly Rs 2,600 crore in fine to Daiichi Sankyo, for "suppressing and misrepresenting" facts about the 2008 deal involving the sale of controlling stake in Ranbaxy to the Japanese drugmaker.

The Japanese company is selling its 8.9 per cent stake in Sun Pharma, India's largest drugmaker by sales, via block deals on the Indian exchanges, said the person, who declined to be named as he was not authorised to speak to the media.

It has been a year of bitter medicine for Indian pharmaceutical companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including a high profile merger between Sun Pharma and Ranbaxy.

The $4 billion merger deal of Ranbaxy with Sun Pharma is expected to close by the end of 2014, Japanese drug maker Daiichi Sankyo, which holds majority stake in the former, said today.

Global investment bank UBS upgraded both Sun Pharma (target Rs 720) and Ranbaxy (target Rs 576) to 'buy' citing 5-10 per cent earning per share accretion in FY17.

Ramesh Adige, former executive director of Ranbaxy told NDTV's Prashant Nair that Sun Pharma's acquisition of Ranbaxy for $3.2 billion is a win-win situation for all stakeholders, except Daiichi, which is the controlling shareholder in Ranbaxy.

Shares in Ranbaxy, however, dropped as much as 5.5 per cent on profit taking. Ranbaxy shares have gained 26 per cent over the last week as compared to a 0.12 per cent drop in the BSE Sensex. Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy. The exchange ratio represents an implied value of Rs 457 for each Ranbaxy ...

Ranbaxy, India's biggest company by sales, is controlled by Japan's Daiichi Sankyo. All of its local units have been under the scanner of the US Food and Drug Administration for manufacturing violations. Currently, Ranbaxy cannot export generic drugs to the US, which is its most important market.

Mumbai-based Sun Pharma will acquire troubled Indian drug maker Ranbaxy in a US$ 4 billion all-stock transaction, the company said in a statement on Monday.